Research Analysts Issue Forecasts for MLYS Q1 Earnings

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Equities researchers at HC Wainwright lifted their Q1 2026 earnings per share estimates for shares of Mineralys Therapeutics in a note issued to investors on Monday, March 16th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($0.44) per share for the quarter, up from their prior forecast of ($0.52). HC Wainwright currently has a “Buy” rating and a $56.00 price target on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.63) EPS, FY2026 earnings at ($2.14) EPS, FY2027 earnings at ($2.40) EPS and FY2028 earnings at ($0.90) EPS.

Several other research analysts have also weighed in on MLYS. Jefferies Financial Group reissued a “hold” rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Thursday, January 22nd. Stifel Nicolaus lifted their price target on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, December 19th. Bank of America boosted their price objective on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research note on Friday. Finally, Wall Street Zen upgraded Mineralys Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Mineralys Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $49.14.

Mineralys Therapeutics Stock Performance

Shares of NASDAQ MLYS opened at $25.02 on Wednesday. The firm’s 50 day moving average price is $30.04 and its 200 day moving average price is $35.79. The firm has a market cap of $2.06 billion, a P/E ratio of -10.56 and a beta of 0.57. Mineralys Therapeutics has a 1 year low of $10.44 and a 1 year high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Thursday, March 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17.

Insider Transactions at Mineralys Therapeutics

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 192,715 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $35.02, for a total value of $6,748,879.30. Following the completion of the transaction, the insider owned 61,804 shares in the company, valued at approximately $2,164,376.08. This represents a 75.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Jon Congleton sold 16,236 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $32.62, for a total transaction of $529,618.32. Following the completion of the sale, the chief executive officer owned 639,151 shares in the company, valued at $20,849,105.62. The trade was a 2.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 363,325 shares of company stock valued at $12,298,347. Insiders own 33.24% of the company’s stock.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MLYS. Smartleaf Asset Management LLC increased its position in Mineralys Therapeutics by 198.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after acquiring an additional 676 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Mineralys Therapeutics by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after purchasing an additional 702 shares in the last quarter. Navalign LLC acquired a new position in shares of Mineralys Therapeutics during the fourth quarter valued at $33,000. Velan Capital Investment Management LP increased its holdings in shares of Mineralys Therapeutics by 0.6% during the third quarter. Velan Capital Investment Management LP now owns 175,600 shares of the company’s stock valued at $6,659,000 after purchasing an additional 1,000 shares during the period. Finally, Royal Bank of Canada raised its stake in shares of Mineralys Therapeutics by 262.3% during the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after purchasing an additional 1,107 shares in the last quarter. 84.46% of the stock is owned by institutional investors.

Key Mineralys Therapeutics News

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Company clinical progress: Mineralys reported 2025 results and said its hypertension drug review advanced, a fundamental win that supports long-term commercial potential. Mineralys reports 2025 results, advances hypertension drug review
• Positive Sentiment: Institutional demand: Several large investors (Goldman Sachs, AQR, Woodline) increased or initiated positions recently, signaling continued institutional appetite that can support the share base. MLYS institutional ownership and MarketBeat summary
• Neutral Sentiment: HC Wainwright maintains a Buy rating and $56 target while issuing a bundle of updated estimates — some short-term quarters are nudged higher and others slightly lower, reflecting fine-tuning rather than a large directional shift in conviction. This leaves the firm’s positive outlook intact even as near-term numbers move. HC Wainwright research notes
• Negative Sentiment: Insider selling: Director/insider David Malcom Rodman sold multiple blocks of shares in March (including 6,348 and 14,058-share transactions), which can pressure sentiment and raise questions for some investors about near-term insider conviction. Insider selling report
• Negative Sentiment: Mixed analyst edits to multi-year outlook: HC Wainwright trimmed FY2027 and FY2028 EPS expectations modestly while boosting FY2029–FY2030 long-term estimates, creating near-term downward revisions that may weigh on sentiment until clinical/commercial catalysts de-risk the model. HC Wainwright EPS revisions

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.